Literature DB >> 24350163

Queries regarding local erythropoietin injection in tibiofibular fracture healing.

Jan Hendrik Duedal Rölfing1, Cody Bünger1.   

Abstract

Entities:  

Keywords:  Bone and Bones; Erythropoietin; Fracture Healing; Orthopedic Procedures; Orthopedics; Tibia

Year:  2013        PMID: 24350163      PMCID: PMC3860679          DOI: 10.5812/traumamon.12192

Source DB:  PubMed          Journal:  Trauma Mon        ISSN: 2251-7472


× No keyword cloud information.
Dear Editor, We would like to congratulate Dr. Bakhshi and colleagues for being the first group to publish scientific evidence regarding the osteogenic effect of erythropoietin (EPO) in a clinical trial (1). As you correctly report, several preclinical studies have shown the efficacy of Erythropoietin to increase bone healing at early time points (2-4).In agreement with your approach, we strongly believe that localized, low-dose administration is the prerequisite for clinical application of recombinant human EPO in the clinical orthopedic setting. Systemic dosage increases risk of known adverse effects such as thromboembolic complications.However, the scientific validity of your study could have been greatly improved if the following steps were followed: first, adherence to CONSORT guidelines regarding randomized clinical trials; especially information about eligibility, enrolment, randomization and blinding procedures should be given; secondly, the treatment regimen, e.g. manufacturer and dosage of EPO specified in more detail (5). For instance, the treatment regimen was described as “EPO (4000 IU) was injected in one group into the fracture site two weeks after the operation and under sterile conditions and guide of a C-arm.” However, after email correspondence, the authors specify that they used three vials in slim patients and up to five vials in obese patients. Tibia fractures span a broad range of injuries. Fracture healing and the likelihood of non-unions highly depends upon the severity of the fracture and soft-tissue injury (6). Excellent classification systems for fracture types and accompanying soft-tissue injury exist and should be used when reporting fracture studies (closed fractures: Oestern and Tscherne, open fractures: Gustilo) (6-8). Were fractures in this study confined to the simple tibia shaft fractures with addition of fibular fracture, corresponding to AO classification types: 42-A1.2, 42-A1.3, 42-A2.2, 42-A2.3, 42-A3.2, and 42-A3.3 (9)? Was there any difference in soft-tissue damage between the treatment and control group? Even though Goldhan et al. suggest multiple radiologic examinations in order to determine possible acceleration of fracture healing, in the light of patient safety concerns, 10 radiologic examinations per patient with 14-day intervals until union was achieved at a mean time of almost 20 weeks seem clinically and ethically unjustified (10)
  8 in total

1.  Erythropoietin augments bone formation in a rabbit posterolateral spinal fusion model.

Authors:  Jan Hendrik Duedal Rölfing; Michael Bendtsen; Jonas Jensen; Maik Stiehler; Casper Bindzus Foldager; Michel Bach Hellfritzsch; Cody Bünger
Journal:  J Orthop Res       Date:  2011-12-05       Impact factor: 3.494

2.  Local erythropoietin injection in tibiofibular fracture healing.

Authors:  Hooman Bakhshi; Gholamhossein Kazemian; Mohammad Emami; Ali Nemati; Hossein Karimi Yarandi; Farshad Safdari
Journal:  Trauma Mon       Date:  2013-01-15

3.  Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses.

Authors:  R B Gustilo; J T Anderson
Journal:  J Bone Joint Surg Am       Date:  1976-06       Impact factor: 5.284

4.  Erythropoietin (EPO): EPO-receptor signaling improves early endochondral ossification and mechanical strength in fracture healing.

Authors:  Joerg H Holstein; Michael D Menger; Claudia Scheuer; Christoph Meier; Ulf Culemann; Rainer J Wirbel; Patric Garcia; Tim Pohlemann
Journal:  Life Sci       Date:  2006-11-21       Impact factor: 5.037

5.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  PLoS Med       Date:  2010-03-24       Impact factor: 11.069

6.  Erythropoietin couples hematopoiesis with bone formation.

Authors:  Yusuke Shiozawa; Younghun Jung; Anne M Ziegler; Elisabeth A Pedersen; Jianhua Wang; Zhuo Wang; Junhui Song; Jingcheng Wang; Clara H Lee; Sudha Sud; Kenneth J Pienta; Paul H Krebsbach; Russell S Taichman
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

7.  Fracture and dislocation classification compendium - 2007: Orthopaedic Trauma Association classification, database and outcomes committee.

Authors:  J L Marsh; Theddy F Slongo; Julie Agel; J Scott Broderick; William Creevey; Thomas A DeCoster; Laura Prokuski; Michael S Sirkin; Bruce Ziran; Brad Henley; Laurent Audigé
Journal:  J Orthop Trauma       Date:  2007 Nov-Dec       Impact factor: 2.512

Review 8.  Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.

Authors:  Jörg Goldhahn; Wim H Scheele; Bruce H Mitlak; Eric Abadie; Per Aspenberg; Peter Augat; Maria-Luisa Brandi; Nansa Burlet; Arkadi Chines; Pierre D Delmas; Isabelle Dupin-Roger; Dominique Ethgen; Beate Hanson; Florian Hartl; John A Kanis; Reshma Kewalramani; Andrea Laslop; David Marsh; Sif Ormarsdottir; René Rizzoli; Art Santora; Gerhard Schmidmaier; Michael Wagener; Jean-Yves Reginster
Journal:  Bone       Date:  2008-05-07       Impact factor: 4.398

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.